Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy
Virax Biolabs Group (NASDAQ: VRAX) believes its technology aligns with the United States Department of Health and Human Services' commitment to prioritizing transparency on vaccine efficacy. This initiative is essential for empowering the public with the information needed to make informed health decisions. Virax Biolabs recognizes the essential role vaccines play in public health and is committed to ensuring vaccine efficacy. The Company asserts the importance of transparency regarding vaccine effectiveness and how individual immune profiles impact vaccination decisions, enabling informed, empowered choices about personal health.
Virax Biolabs is positioned to advance vaccine transparency in collaboration with companies developing vaccines. Our cutting-edge technology enables us to provide research-based tools to measure the efficacy of the vaccines as well as monitor long-term immune protection for individuals following vaccination. These solutions further capitalize on Virax Biolabs' innovative platform to deliver comprehensive immune profiling solutions, with a focus on advancing research in protective immunity and T cell dysfunction.
"As this new administration appears to enter a new era of vaccine transparency, we believe Virax Biolabs is well-positioned to provide additional critical, data-driven insights on vaccine efficacy to support existing and future vaccine development," said James Foster, Chief Executive Officer of Virax Biolabs. "We are fully aligned in supporting Public Health initiatives around Vaccine Efficacy Testing."
Virax Biolabs Group (NASDAQ: VRAX) crede che la sua tecnologia si allinei con l'impegno del Dipartimento della Salute e dei Servizi Umani degli Stati Uniti a dare priorità alla trasparenza sull'efficacia dei vaccini. Questa iniziativa è fondamentale per fornire al pubblico le informazioni necessarie per prendere decisioni informate sulla salute. Virax Biolabs riconosce il ruolo essenziale che i vaccini svolgono nella salute pubblica e si impegna a garantire l'efficacia dei vaccini. L'azienda sottolinea l'importanza della trasparenza riguardo all'efficacia dei vaccini e a come i profili immunitari individuali influenzino le decisioni di vaccinazione, consentendo scelte informate e consapevoli sulla salute personale.
Virax Biolabs è posizionata per promuovere la trasparenza sui vaccini in collaborazione con aziende che sviluppano vaccini. La nostra tecnologia all'avanguardia ci consente di fornire strumenti basati sulla ricerca per misurare l'efficacia dei vaccini e monitorare la protezione immunitaria a lungo termine per gli individui dopo la vaccinazione. Queste soluzioni capitalizzano ulteriormente sulla piattaforma innovativa di Virax Biolabs per offrire soluzioni complete di profilazione immunitaria, con un focus sull'avanzamento della ricerca nell'immunità protettiva e nella disfunzione delle cellule T.
“Poiché questa nuova amministrazione sembra entrare in una nuova era di trasparenza sui vaccini, riteniamo che Virax Biolabs sia ben posizionata per fornire ulteriori informazioni critiche, basate sui dati, sull'efficacia dei vaccini per supportare lo sviluppo di vaccini esistenti e futuri,” ha dichiarato James Foster, Amministratore Delegato di Virax Biolabs. “Siamo completamente allineati nel supportare le iniziative di Salute Pubblica relative ai test di efficacia dei vaccini.”
Virax Biolabs Group (NASDAQ: VRAX) cree que su tecnología se alinea con el compromiso del Departamento de Salud y Servicios Humanos de los Estados Unidos de priorizar la transparencia sobre la eficacia de las vacunas. Esta iniciativa es esencial para empoderar al público con la información necesaria para tomar decisiones de salud informadas. Virax Biolabs reconoce el papel esencial que juegan las vacunas en la salud pública y se compromete a garantizar la eficacia de las vacunas. La empresa afirma la importancia de la transparencia respecto a la efectividad de las vacunas y cómo los perfiles inmunitarios individuales impactan las decisiones de vacunación, permitiendo elecciones informadas y empoderadas sobre la salud personal.
Virax Biolabs está posicionada para avanzar en la transparencia de las vacunas en colaboración con empresas que desarrollan vacunas. Nuestra tecnología de vanguardia nos permite proporcionar herramientas basadas en la investigación para medir la eficacia de las vacunas, así como monitorear la protección inmunitaria a largo plazo para las personas después de la vacunación. Estas soluciones aprovechan aún más la plataforma innovadora de Virax Biolabs para ofrecer soluciones integrales de perfilado inmunitario, con un enfoque en avanzar en la investigación sobre la inmunidad protectora y la disfunción de células T.
“A medida que esta nueva administración parece entrar en una nueva era de transparencia sobre las vacunas, creemos que Virax Biolabs está bien posicionada para proporcionar información crítica adicional, basada en datos, sobre la eficacia de las vacunas para apoyar el desarrollo de vacunas existentes y futuras,” dijo James Foster, Director Ejecutivo de Virax Biolabs. “Estamos completamente alineados en apoyar las iniciativas de Salud Pública en torno a las Pruebas de Eficacia de Vacunas.”
Virax Biolabs Group (NASDAQ: VRAX)는 자사의 기술이 미국 보건복지부의 백신 효능에 대한 투명성을 우선시하는 약속과 일치한다고 믿습니다. 이 이니셔티브는 대중이 정보에 기반한 건강 결정을 내릴 수 있도록 하는 데 필수적입니다. Virax Biolabs는 백신이 공공 건강에서 중요한 역할을 한다는 것을 인식하고 있으며, 백신의 효능을 보장하기 위해 노력하고 있습니다. 이 회사는 백신의 효과에 대한 투명성과 개인의 면역 프로필이 백신 접종 결정에 미치는 영향을 강조하며, 개인 건강에 대한 정보에 기반한 선택을 가능하게 합니다.
Virax Biolabs는 백신을 개발하는 회사들과 협력하여 백신의 투명성을 증진할 수 있는 위치에 있습니다. 우리의 최첨단 기술은 백신의 효능을 측정하고 백신 접종 후 개인의 장기 면역 보호를 모니터링하는 연구 기반 도구를 제공할 수 있게 해줍니다. 이러한 솔루션은 Virax Biolabs의 혁신적인 플랫폼을 활용하여 보호 면역 및 T세포 기능 장애에 대한 연구를 발전시키는 데 중점을 두고 포괄적인 면역 프로파일링 솔루션을 제공합니다.
“이 새로운 행정부가 백신 투명성의 새로운 시대에 접어드는 것처럼 보이는 가운데, 우리는 Virax Biolabs가 기존 및 미래의 백신 개발을 지원하기 위해 백신 효능에 대한 추가적인 중요한 데이터 기반 통찰력을 제공할 수 있는 좋은 위치에 있다고 믿습니다,”라고 Virax Biolabs의 CEO인 James Foster가 말했습니다. “우리는 백신 효능 테스트와 관련된 공공 건강 이니셔티브를 전적으로 지원하는 데 동의합니다.”
Virax Biolabs Group (NASDAQ: VRAX) croit que sa technologie s'aligne sur l'engagement du Département de la Santé et des Services sociaux des États-Unis à prioriser la transparence sur l'efficacité des vaccins. Cette initiative est essentielle pour donner au public les informations nécessaires pour prendre des décisions éclairées en matière de santé. Virax Biolabs reconnaît le rôle essentiel des vaccins dans la santé publique et s'engage à garantir l'efficacité des vaccins. L'entreprise souligne l'importance de la transparence concernant l'efficacité des vaccins et comment les profils immunitaires individuels influencent les décisions de vaccination, permettant des choix éclairés et autonomes en matière de santé personnelle.
Virax Biolabs est positionnée pour faire avancer la transparence des vaccins en collaboration avec des entreprises développant des vaccins. Notre technologie de pointe nous permet de fournir des outils basés sur la recherche pour mesurer l'efficacité des vaccins ainsi que de surveiller la protection immunitaire à long terme des individus après la vaccination. Ces solutions tirent également parti de la plateforme innovante de Virax Biolabs pour offrir des solutions complètes de profilage immunitaire, en mettant l'accent sur l'avancement de la recherche sur l'immunité protectrice et la dysfonction des cellules T.
“Alors que cette nouvelle administration semble entrer dans une nouvelle ère de transparence sur les vaccins, nous croyons que Virax Biolabs est bien positionnée pour fournir des informations critiques supplémentaires, basées sur des données, sur l'efficacité des vaccins pour soutenir le développement de vaccins existants et futurs,” a déclaré James Foster, directeur général de Virax Biolabs. “Nous sommes pleinement alignés pour soutenir les initiatives de santé publique concernant les tests d'efficacité des vaccins.”
Virax Biolabs Group (NASDAQ: VRAX) glaubt, dass seine Technologie mit dem Engagement des US-Gesundheitsministeriums übereinstimmt, Transparenz bei der Wirksamkeit von Impfstoffen zu priorisieren. Diese Initiative ist entscheidend, um der Öffentlichkeit die Informationen zu geben, die sie benötigt, um informierte Gesundheitsentscheidungen zu treffen. Virax Biolabs erkennt die wesentliche Rolle an, die Impfstoffe für die öffentliche Gesundheit spielen, und verpflichtet sich, die Wirksamkeit von Impfstoffen sicherzustellen. Das Unternehmen betont die Bedeutung von Transparenz in Bezug auf die Wirksamkeit von Impfstoffen und wie individuelle Immunprofile die Impfentscheidungen beeinflussen, um informierte und befähigte Entscheidungen über die persönliche Gesundheit zu ermöglichen.
Virax Biolabs ist in der Lage, die Transparenz von Impfstoffen in Zusammenarbeit mit Unternehmen zu fördern, die Impfstoffe entwickeln. Unsere hochmoderne Technologie ermöglicht es uns, forschungsbasierte Werkzeuge zur Messung der Wirksamkeit von Impfstoffen bereitzustellen und den langfristigen Immunschutz für Einzelpersonen nach der Impfung zu überwachen. Diese Lösungen nutzen die innovative Plattform von Virax Biolabs weiter, um umfassende Immunprofilierungslösungen anzubieten, mit einem Fokus auf die Förderung der Forschung zur schützenden Immunität und zur T-Zell-Dysfunktion.
„Da diese neue Verwaltung anscheinend in eine neue Ära der Impfstofftransparenz eintritt, glauben wir, dass Virax Biolabs gut positioniert ist, um zusätzliche kritische, datengestützte Einblicke in die Wirksamkeit von Impfstoffen zu bieten, um die bestehende und zukünftige Impfstoffentwicklung zu unterstützen“, sagte James Foster, CEO von Virax Biolabs. „Wir sind voll und ganz darauf ausgerichtet, die Initiativen der öffentlichen Gesundheit im Bereich der Impfstoffwirksamkeitstests zu unterstützen.“
- Positioned to advance vaccine transparency.
- Cutting-edge technology for vaccine efficacy measurement.
- Comprehensive immune profiling solutions.
- Collaboration with vaccine developers.
- None.
Company Positioned to Support Public Health through Vaccine Efficacy Testing and Data-Driven Insights into Patients' Immune Profiles to Empower Informed Decisions on Vaccination
Virax Biolabs recognizes the essential role vaccines play in public health and is committed to ensuring vaccine efficacy. The Company asserts the importance of transparency regarding vaccine effectiveness and how individual immune profiles impact vaccination decisions, enabling informed, empowered choices about personal health.
Virax Biolabs is positioned to advance vaccine transparency in collaboration with companies developing vaccines. Our cutting-edge technology enables us to provide research-based tools to measure efficacy of the vaccines as well as monitor long term immune protection for individuals following vaccination. These solutions further capitalize on Virax Biolabs' innovative platform to deliver comprehensive immune profiling solutions, with a focus on advancing research in protective immunity and T cell dysfunction.
"As this new administration appears to enter a new era of vaccine transparency, we believe Virax Biolabs is well-positioned to provide additional critical, data-driven insights on vaccine efficacy to support existing and future vaccine development," said James Foster, Chief Executive Officer of Virax Biolabs. "We are fully aligned in supporting Public Health initiatives around Vaccine Efficacy Testing."
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Caution Concerning Forward-looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "intends," "potential," or "hopes" or the negative of these or similar terms. Forward-looking statements are only predictions. The forward-looking events discussed in this press release, and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; successful development of our intended products; our ability to gain regulatory approval to offer our products or services in our targeted markets; our ability to keep pace with new technology and changing market needs; protection of our intellectual property rights; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2024. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-believes-technology-aligns-with-united-states-department-of-health-and-human-services-transparency-priority-on-vaccine-efficacy-302383365.html
SOURCE Virax Biolabs
FAQ
What does Virax Biolabs' alignment with the US Department of Health and Human Services mean for VRAX shareholders?
How does Virax Biolabs' technology support vaccine efficacy?
What are the key benefits of Virax Biolabs' immune profiling solutions?
How might Virax Biolabs' collaboration with vaccine developers impact VRAX stock?
What is the significance of Virax Biolabs' focus on T cell dysfunction?
